Individualizing Frontline Treatment Selection in Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman introduce the first clinical scenario featuring a young woman with newly diagnosed metastatic triple-negative breast cancer (mTNBC) and discuss the clinical and personal factors that influence frontline treatment selection. Using this case, the faculty emphasize the importance of taking a holistic, patient-centered approach that considers disease burden, biomarker results, performance status, quality-of-life goals, work responsibilities, family obligations, and logistical factors such as treatment scheduling and transportation. NP Zafman highlights that multiple frontline antibody-drug conjugate (ADC) options may be appropriate for eligible patients and explains how differences in treatment administration, toxicity profiles, and supportive care requirements should be incorporated into shared decision-making. Throughout the discussion, NP Stukus and NP Zafman reinforce that selecting frontline therapy extends beyond clinical efficacy alone and should align with each patient's individual priorities, lifestyle, and treatment goals to optimize outcomes for patients with metastatic triple-negative breast cancer.